Statement: There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.
Primary_evidence: Inclusion Criteria:   Histologically and/or cytologically confirmed breast cancer   Received adjuvant/neo-adjuvant chemotherapy for breast cancer with anthracycline regimen   To have at least one measurable region   Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1   To have adequate organ function (bone marrow, liver and renal function) Exclusion Criteria:   To have interstitial pneumonia or pulmonary fibrosis   To have inflammatory breast cancer   Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery   To have brain metastases with symptoms   To have severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)
Secondary_evidence: Inclusion Criteria:   Age: no limit   Karnofsky performance status (KPS)  70   No more than 5 metastatic sites involving one or more different organs (liver, lung or bone).   The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol.   Previously treated lesions are not eligible unless the prescribed dose can be safely delivered.   Concurrent therapy is allowed and recommended. The chemotherapy protocol type and schedule are at the discretion of the medical oncologist.   Informed consent must be obtained.   Pregnancy test must be negative for women of child bearing potential Exclusion Criteria:   Inability of patient to be followed longitudinally as specified by protocol.   Technical inability to achieve required dose based on safe dose constraints required for radiosurgery.   Women who are pregnant or nursing.   Failure to meet requirements in Inclusion Criteria   Contraindications to radiation.